Aaron Z Hettinger
Overview
Explore the profile of Aaron Z Hettinger including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
109
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Saunders-Hastings P, Zhou C, Hobbi S, Boyd E, Lloyd P, Alawar N, et al.
Pathogens
. 2023 Mar;
12(3).
PMID: 36986311
COVID-19 infections have contributed to substantial increases in hospitalizations. This study describes demographics, baseline clinical characteristics and treatments, and clinical outcomes among U.S. patients admitted to hospitals with COVID-19 during...
2.
Pruitt Z, Kazi S, Weir C, Taft T, Busog D, Ratwani R, et al.
Appl Clin Inform
. 2023 Mar;
14(1):185-198.
PMID: 36889339
Background: Although electronic medication administration records (eMARs) and bar-coded medication administration (BCMA) have improved medication safety, poor usability of these technologies can increase patient safety risks. Objectives: The objective of...
3.
Taft T, Rudd E, Thraen I, Kazi S, Pruitt Z, Bonk C, et al.
J Am Med Inform Assoc
. 2023 Mar;
30(5):809-818.
PMID: 36888889
Objectives: (1) Characterize persistent hazards and inefficiencies in inpatient medication administration; (2) Explore cognitive attributes of medication administration tasks; and (3) Discuss strategies to reduce medication administration technology-related hazards. Materials...
4.
Whitaker B, Pizarro J, Deady M, Williams A, Ezzeldin H, Belov A, et al.
Transfusion
. 2022 Aug;
62(10):2029-2038.
PMID: 36004803
Background: Transfusion-related adverse events can be unrecognized and unreported. As part of the US Food and Drug Administration's Center for Biologics Evaluation and Research Biologics Effectiveness and Safety initiative, we...
5.
Kandaswamy S, Grimes J, Hoffman D, Marquard J, Ratwani R, Hettinger A
J Patient Saf
. 2022 Aug;
18(5):430-434.
PMID: 35948292
Objectives: Medication information is frequently communicated via free-text computerized provider order entry (CPOE) orders in electronic health records. When such information is transmitted separately from a structured CPOE medication order,...
6.
Kandaswamy S, Pruitt Z, Kazi S, Marquard J, Owens S, Hoffman D, et al.
Appl Clin Inform
. 2021 Jun;
12(3):484-494.
PMID: 34077971
Objective: The aim of this study was to investigate (1) why ordering clinicians use free-text orders to communicate medication information; (2) what risks physicians and nurses perceive when free-text orders...
7.
Adams K, Pruitt Z, Kazi S, Hettinger A, Howe J, Fong A, et al.
J Patient Saf
. 2021 May;
17(8):e988-e994.
PMID: 34009868
Objective: Different health information technology (health IT) systems are intended to support medication ordering, reviewing, and administration. We sought to identify the types of medication errors associated with health IT...
8.
Pruitt Z, Howe J, Hettinger A, Ratwani R
J Patient Saf
. 2021 Apr;
17(8):e983-e987.
PMID: 33871414
Objectives: Despite requirements for electronic health record (EHR) vendor usability testing, usability challenges persist, contributing to patient safety concerns. We sought to identify emergency physicians' perceived EHR usability and safety...
9.
Hettinger A, Melnick E, Ratwani R
J Am Med Inform Assoc
. 2021 Jan;
28(5):1029-1031.
PMID: 33517394
Despite basic federal requirements promoting a user-centered design approach to electronic health record (EHR) development and usability testing there have been usability and safety risks with EHR technology. Four EHR...
10.
Shenoy A, Hettinger A, Fernandez S, Blumenthal J, Baez V
Br J Haematol
. 2021 Jan;
192(4):706-713.
PMID: 33482025
Convalescent plasma can provide passive immunity during viral outbreaks, but the benefit is uncertain for the treatment of novel coronavirus disease 2019 (COVID-19). Our goal is to assess the efficacy...